Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals

Breast Cancer Research

Volumn 13, Issue 1, 2011, Pages

  Kuusisto, Kirsi M ^a,b   Bebel, Aleksandra ^a   Vihinen, Mauno ^a   Schleutker, Johanna ^a,b   Sallinen, Satu Leena ^b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; BRCA1 INTERACTING PROTEIN 1; BRCA1 PROTEIN; BRCA2 PROTEIN; CADHERIN 1; CHECKPOINT KINASE 2; PARTNER AND LOCALIZER OF BRCA2; PROTEIN; RAD50 PROTEIN; UNCLASSIFIED DRUG; BRIP1 PROTEIN, HUMAN; CADHERIN; CDH1 PROTEIN, HUMAN; DNA BINDING PROTEIN; MICRORNA; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RAD50 PROTEIN, HUMAN; RNA HELICASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; COMPUTER MODEL; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERM LINE; HIGH RESOLUTION MELTING ANALYSIS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PEDIGREE; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; ALLELE; BREAST TUMOR; FINLAND; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; OVARY TUMOR; PATHOLOGY; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

ADULT; AGED; ALLELES; AMINO ACID SUBSTITUTION; BREAST NEOPLASMS; CADHERINS; CHECKPOINT KINASE 2; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; FINLAND; GENE FREQUENCY; GENES, BRCA1; GENES, BRCA2; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MICRORNAS; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PEDIGREE; RNA HELICASES; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84860389325     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2832     Document Type: Article

References (47)

1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996, 77(11):2318-2324. 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z, 8635102.
2. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266(5182):66-71. 10.1126/science.7545954, 7545954.
3. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996, 12:333-337. 10.1038/ng0396-333, 8589730.
4. Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjakoski K, Pyrhonen S, Kallioniemi OP, Muhonen T, Luce M, Frank TS, Nevanlinna H. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 1997, 6:2309-2315. 10.1093/hmg/6.13.2309, 9361038.
5. Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000, 92:1529-1531. 10.1093/jnci/92.18.1529, 10995809.
6. Li FP, Fraumeni JF. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969, 43:1365-1373.
7. Starink TM, van der Veen JP, Arwert F, de Waal LP, de Lange GG, Gille JJ, Eriksson AW. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 1986, 29:222-233. 10.1111/j.1399-0004.1986.tb00816.x, 3698331.
8. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000, 119:1447-1453. 10.1053/gast.2000.20228, 11113065.
9. Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, Grundei T, Becker KF, Mueller J, Siewert JR, Hofler H. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 1999, 155:337-342. 10.1016/S0002-9440(10)65129-2, 1866861, 10433926.
10. Welcsh PL, Owens KN, King MC. Insights into the functions of BRCA1 and BRCA2. Trends Genet 2000, 16:69-74. 10.1016/S0168-9525(99)01930-7, 10652533.
11. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002, 71:432-438. 10.1086/341943, 379177, 12094328.
12. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen S, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma V, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007, 446:316-319. 10.1038/nature05609, 17287723.
13. Vahteristo P, Yliannala K, Tamminen A, Eerola H, Blomqvist C, Nevanlinna H. BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer 2006, 6:19. 10.1186/1471-2407-6-19, 1368988, 16430786.
14. Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundan T, Mannermaa A, Borresen-Dale AL, Borg A, Barkardottir RB, Petrini J, Winqvist R. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 2006, 27:1593-1599. 10.1093/carcin/bgi360, 3006189, 16474176.
15. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405. 10.1038/32918, 9537325.
16. Easton DF. How many more breast cancer predisposition genes are there?. Breast Cancer Res 1999, 1:14-17. 10.1186/bcr6, 138504, 11250676.
17. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene 2006, 25:5898-5905. 10.1038/sj.onc.1209879, 16998504.
18. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, et al. SEARCH collaborators Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093. 10.1038/nature05887, 2714974, 17529967, SEARCH collaborators.
19. Tommiska J, Seal S, Renwick A, Barfoot R, Baskcomb L, Jayatilake H, Bartkova J, Tallila J, Kaare M, Tamminen A, Heikkila P, Evans DG, Eccles D, Aittomaki K, Blomqvist C, Bartek J, Stratton MR, Nevanlinna H, Rahman N. Evaluation of RAD50 in familial breast cancer predisposition. Int J Cancer 2006, 118:2911-2916. 10.1002/ijc.21738, 16385572.
20. Rozen S, Skaletsky H. Primer3 on the www for general users and for biologist programmers. Methods Mol Biol 2000, 132:365-386.
21. Two by two table analysis online. Including chi-square, odds ratio, risk ratio. , http://www.quantitativeskills.com/sisa/statistics/twoby2.htm
22. Thusberg J, Vihinen M. Pathogenic or not? And if so, then how? Studying the effects of missense mutations using bioinformatics methods. Hum Mutat 2009, 30:703-714. 10.1002/humu.20938, 19267389.
23. miRBase. , http://www.mirbase.org/
24. BLAST: Basic Local Alignment Search Tool. , http://blast.ncbi.nlm.nih.gov/Blast.cgi
25. Chen P, Liang J, Wang Z, Zhou X, Chen L, Li M, Xie D, Hu Z, Shen H, Wang H. Association of common PALB2 polymorphisms with breast cancer risk: a case-control study. Clin Cancer Res 2008, 14:5931-5937. 10.1158/1078-0432.CCR-08-0429, 18794107.
26. Mazoyer S. Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat 2005, 25:415-422. 10.1002/humu.20169, 15832305.
27. Pylkas K, Erkko H, Nikkila J, Solyom S, Winqvist R. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC Cancer 2008, 8:146. 10.1186/1471-2407-8-146, 2413256, 18501021.
28. Ostrow KL, McGuire V, Whittemore AS, DiCioccio RA. The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity. Cancer Genet Cytogenet 2004, 153:177-180. 10.1016/j.cancergencyto.2004.01.020, 15350310.
29. Phelan CM, Dapic V, Tice B, Favis R, Kwan E, Barany F, Manoukian S, Radice P, van der Luijt RB, van Nesselrooij BP, Chenevix-Trench G, kConFab, Caldes T, de la Hoya M, Lindquist S, Tavtigian SV, Goldgar D, Borg A, Narod SA, Monteiro AN. Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet 2005, 42:138-146. 10.1136/jmg.2004.024711, 1735988, 15689452.
30. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006, 22:719-729. 10.1016/j.molcel.2006.05.022, 16793542.
31. Deffenbaugh AM, Frank TS, Hoffman M, Cannon-Albright L, Neuhausen SL. Characterization of common BRCA1 and BRCA2 variants. Genet Test 2002, 6:119-121. 10.1089/10906570260199375, 12215251.
32. Wagner TM, Hirtenlehner K, Shen P, Moeslinger R, Muhr D, Fleischmann E, Concin H, Doeller W, Haid A, Lang AH, Mayer P, Petru E, Ropp E, Langbauer G, Kubista E, Scheiner O, Underhill P, Mountain J, Stierer M, Zielinski C, Oefner P. Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet 1999, 8:413-423. 10.1093/hmg/8.3.413, 9971877.
33. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, Gayther SA, Mangion J, Stratton MR, Lynch HT, Goldgar DE, Ponder BA, Lenoir GM. A polymorphic stop codon in BRCA2. Nat Genet 1996, 14:253-254. 10.1038/ng1196-253, 8896551.
34. CHEK2 Breast Cancer Case-Control Consortium CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004, 74:1175-1182. 10.1086/421251, 1182081, 15122511, CHEK2 Breast Cancer Case-Control Consortium.
35. Kilpivaara O, Vahteristo P, Falck J, Syrjakoski K, Eerola H, Easton D, Bartkova J, Lukas J, Heikkila P, Aittomaki K, Holli K, Blomqvist C, Kallioniemi OP, Bartek J, Nevanlinna H. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 2004, 111:543-547. 10.1002/ijc.20299, 15239132.
36. Seppala EH, Ikonen T, Mononen N, Autio V, Rokman A, Matikainen MP, Tammela TL, Schleutker J. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003, 89:1966-1970. 10.1038/sj.bjc.6601425, 2394451, 14612911.
37. Kilpivaara O, Laiho P, Aaltonen LA, Nevanlinna H. CHEK2 1100delC and colorectal cancer. J Med Genet 2003, 40:e110. 10.1136/jmg.40.10.e110, 1735285, 14569133.
38. Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna H. CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 2006, 43:e34. 10.1136/jmg.2005.038331, 2564563, 16816021.
39. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006, 25:5912-5919. 10.1038/sj.onc.1209877, 16998506.
40. Ripperger T, Gadzicki D, Meindl A, Schlegelberger B. Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet 2009, 17:722-731. 10.1038/ejhg.2008.212, 2947107, 19092773.
41. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR. Breast Cancer Susceptibility Collaboration (UK) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007, 39:165-167. 10.1038/ng1959, 2871593, 17200668, Breast Cancer Susceptibility Collaboration (UK).
42. Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, Livingston DM. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 2001, 105:149-160. 10.1016/S0092-8674(01)00304-X, 11301010.
43. Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, Tung N, Oliveira C, Collins L, Schnitt S, Garber JE, Huntsman D. Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 2007, 44:726-731. 10.1136/jmg.2007.051268, 2752184, 17660459.
44. UCSC Genome Browser Home. , http://genome.ucsc.edu/
45. ExPASy - UniProt Knowledgebase: Swiss-Prot and TrEMBL. , http://au.expasy.org/sprot/
46. SNP Home. , http://www.ncbi.nlm.nih.gov/snp
47. Breast Cancer Information Core. , http://research.nhgri.nih.gov/bic/